Source: Ejlertsen , B , Tuxen , M K , Jakobsen , E H , Jensen , M-B , Knoop , A S , Højris , I , Ewertz , M , Balslev , E , Danø , H , Vestlev , P M , Kenholm , J , Nielsen , D L , Bechmann , T , Andersson

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

Subjects: Cancérologie; Anthracyclines -- therapeutic use; Antigens, Neoplasm -- genetics

Source: Journal of clinical oncology, 33 (15

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

Subjects: Cancérologie; Anthracyclines -- therapeutic use; Antigens, Neoplasm -- genetics

Source: Journal of clinical oncology, 33 (15

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Subjects: Cancérologie; Médecine pathologie humaine; Sciences bio-médicales et agricoles

Source: Future oncology, 9 (10

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Subjects: Cancérologie; Médecine pathologie humaine; Sciences bio-médicales et agricoles

Source: Future oncology, 9 (10

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Subjects: Cancérologie; Anthracyclines -- administration & dosage; Antigens, Neoplasm -- genetics

Source: Lancet oncology, 12 (12

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Subjects: Cancérologie; Anthracyclines -- administration & dosage; Antigens, Neoplasm -- genetics

Source: Lancet oncology, 12 (12

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study.

Subjects: Cancérologie; Algorithms; Antigens, Neoplasm -- genetics

Source: Journal of theoretical biology, 266 (1

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

Doubling back on centromere 17 in early breast cancer.

Subjects: Cancérologie; Antibiotics, Antineoplastic -- administration & dosage -- pharmacology; Antigens, Neoplasm -- genetics

Source: Lancet oncology, 11 (3

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Electronic Resource

Doubling back on centromere 17 in early breast cancer.

Subjects: Cancérologie; Antibiotics, Antineoplastic -- administration & dosage -- pharmacology; Antigens, Neoplasm -- genetics

Source: Lancet oncology, 11 (3

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer:DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study.

Doubling back on centromere 17 in early breast cancer.

Doubling back on centromere 17 in early breast cancer.

اتصل بنا

اتبع